The latest domestic sales price of Rucaparib

Rucaparib (Rucaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor, mainly used to treat ovarian cancer patients carrying BRCA gene mutations. This drug increases the sensitivity of tumor cells to DNA damage by inhibiting the DNA repair mechanism, thereby inhibiting the growth of tumor cells. Currently, rucapanib is not yet available in China, and patients cannot purchase the drug domestically. In overseas markets, the price of the European version of the original drug Rucapani is approximately RMB 38,000 (300 mg × 60 tablets), but the price may change due to exchange rate fluctuations.

The main indications for rucapanib include the treatment of patients with ovarian cancer who carryBRCA1 or BRCA2 gene mutations, especially those whose disease has progressed despite having received at least two chemotherapy regimens. In addition, rucaparib is being studied for use in other types of tumors, such as breast and prostate cancer, particularly in patients with BRCA mutations.

There is no exact time frame for resistance to rucapanib. The emergence of drug resistance may be related to factors such as the heterogeneity of tumor cells, activation of DNA repair pathways, and drug concentration. Therefore, patients should undergo regular medical evaluation during treatment with rucaparib to monitor efficacy and possible development of resistance.

The effectiveness of rucapanib in the treatment of ovarian cancer has been proven in multiple clinical trials. These studies show that rucapanib can significantly prolong progression-free survival in patients, especially in patients with BRCA gene mutations. However, the therapeutic effect may vary depending on the patient's specific situation, so when treating with rucapanib, individualized treatment should be carried out under the guidance of a physician.

In short, rucapanib, as aPARP inhibitor, has potential efficacy in the treatment of ovarian cancer related to BRCA gene mutations. Although it is not currently available in China, it may be launched in the Chinese market in the future as global drug regulation progresses.

Reference materials:https://www.drugs.com/mtm/rucaparib.html